Ankylosing Spondylitis News and Research

RSS

Ankylosing Spondylitis (AS) is a painful and progressive form of spinal arthritis and symptoms of inflammatory back pain often first present in people before age 35. It typically begins in the late teens and early twenties and in severe cases may result in fusing spinal vertebrae and may cause structural damage to hips and other joints. Often misdiagnosed as "just back pain" or undifferentiated arthritis, AS is a systemic inflammatory disease that, in addition to its effect on the spine, can affect internal organs, peripheral joints and vision. The Arthritis Research Campaign, estimates that on the European continent, AS prevalence ranges from 0.2 to 1 percent of the entire population. The Spondylitis Association of America estimates that between 350,000 and one million people in the U.S. suffer from Ankylosing Spondylitis.

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

MSU researchers move one step closer to solving arthritic disease in teenagers

A new Michigan State University study has found that a malfunctioning gene associated with a common arthritic disease that often starts in teenagers is now directly linked to the loss of vital immune cells that may prevent it.

24 Aug 2018

Researchers discover new protein that controls level of inflammation-inducing molecule

One of the major therapeutic targets for inflammatory diseases is the inflammation-inducing molecule TNF. However, excess levels of TNF cause side effects and can lead to diseases.

27 Jul 2018

Biosimilar competition may offer hope for cheaper, better psoriasis treatments in the future

A new study by iData Research estimates that there are nearly 150,000 new cases of psoriasis every year in the United States, affecting 2.2% of the population.

20 Jun 2018

Combination of NSAIDs and TNF inhibitors linked to reduced radiographic progression in AS patients

Celecoxib combined with TNF inhibitors was associated with the greatest reduction in radiographic progression.

14 Jun 2018

Price check on drug ads: Would revealing costs help patients control spending?

President Donald Trump wants to control spending on drugs. One of his big ideas: include prices in advertisements, just like warnings about side effects.

6 Jun 2018

New study launched to examine effects of rheumatologic agent on bone health

Researchers at Hospital for Special Surgery have launched a pilot study to see how a drug that treats several related autoimmune disorders affects the skeleton.

7 May 2018

Online consultation via mobile app reduces costs and delays for rheumatic disease patients

Researchers in China have developed a new online consultation tool for rheumatic disease patients, which may strengthen the interaction between doctors and patients and lead to more efficient management of chronic illness, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.

6 Nov 2017

New guidelines for anti-rheumatic drug management in patients having joint replacement surgery

In the first such collaboration of its kind, an expert panel of rheumatologists and orthopedic surgeons has developed guidelines for the perioperative management of anti-rheumatic medication in patients undergoing total hip or knee replacement.

16 Jun 2017

Research findings provide insight into mechanisms underlying differences in efficacy of anti-TNF drugs

Osaka University-led researchers identified differences in how three drugs bind to tumor necrosis factor, a key mediator of inflammatory disease. The team used sedimentation velocity analytical ultracentrifugation to investigate drug-target binding in a physiological environment and at clinically-relevant concentrations.

15 May 2017

CreakyJoints publishes new guidelines for rheumatoid arthritis patients and caregivers

CreakyJoints®, the go-to source for more than 100,000 arthritis patients and their families world-wide who are seeking education, support, advocacy and patient-centered research, today announced the publication of “Raising the Voice of the Patients: A Patient’s Guide to Living with Rheumatoid Arthritis”.

25 Jan 2017

CreakyJoints announces first patient-friendly guidelines for rheumatoid arthritis

CreakyJoints, the go-to source for more than 100,000 arthritis patients and their families world-wide who are seeking education, support, advocacy, and patient-centered research, today announced the forthcoming publication of “A Patient’s Guide to Living with Rheumatoid Arthritis.”

15 Nov 2016

FDA approves expanded use of systemic therapy for treating chronic moderate-to-severe pediatric psoriasis

Amgen today announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for the expanded use of ENBREL (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis.

7 Nov 2016

FDA approves new biosimilar for multiple inflammatory diseases

The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases.

23 Sep 2016

Swimming can be effective option for treating patients with fibromyalgia pain

A study performed by researchers at the Federal University of São Paulo shows swimming is as effective as walking to relieve pain and improve quality of life for patients with fibromyalgia.

19 Aug 2016

Facebook advertising could be more effective way of identifying IBP patients

The results of a UK study presented today at the European League Against Rheumatism Annual Congress showed that busing Facebook to raise awareness about the symptoms of Inflammatory Back Pain (IBP) and the need to seek medical help early may reduce the delay in diagnosis and treatment.

13 Jun 2016

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that when antibodies develop in response to the biological treatment Remicade (infliximab), they also cross-react with the biosimilar of infliximab (CT-P13: Inflectra or Remsima).

10 Jun 2016

Ankylosing Spondylitis News and Research

Further Reading